Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.33 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340940 | 0.77 | LMNA (0.41) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL11965624 | 0.77 | LMNA (0.41) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL19534468 | 0.76 | CYP3A4 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL19298159 | 0.76 | CYP3A4 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL19295878 | 0.76 | CYP3A4 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL19283199 | 0.76 | CYP3A4 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL13066077 | 0.76 | POLA1 (0.44) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL21418772 | 0.76 | CYP3A4 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL21418788 | 0.76 | CYP3A4 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 | |
| SCHEMBL16576283 | 0.76 | CYP3A4 (0.46) | LMNATHRBSMN1; SMN2HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2002018404-A9 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HOFFMANN LA ROCHE (CH) | 2003-10-02 | — | — | WO | disclosed |
| EP-1315736-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | LMNA 4330/4885THRB 4383/4885SMN1; SMN2 4281/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | LMNA 4330/4885THRB 4383/4885SMN1; SMN2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.